Pay in 4 interest-free payments of $28.98 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
29-pentaoxo-1
InChi: InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27
Mattheyses AL
PubMed PMID: 21368229
Ansamitocin P-3' showed potential antineoplastic and antimitotic activity
Brivanib 142-70 29-pentaoxo-1Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Product information CAS
US$ 27.48
US$ 39.98
US$ 12.25